Skip to content

Preventing Adverse Drug Events With PatientSite

Preventing Adverse Drug Events With PatientSite

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00140504
Enrollment
800
Registered
2005-09-01
Start date
2003-04-30
Completion date
2004-12-31
Last updated
2013-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse Drug Event

Keywords

Adverse drug event, Patient safety, Internet portal, PatientSite, Preventive health, Primary care

Brief summary

This is a study to better understand the nature and extent of adverse drug events (ADEs), defined as injuries due to prescription medications, in primary care. We will study whether PatientSite (an internet-based communication program for patients and health care providers) can improve clinicians' ability to detect adverse drug events among primary care patients and to mitigate the consequences by sending electronic queries to patients after they receive new medication prescriptions.

Detailed description

* A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested. * Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety. * To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls. * This study will run for 12 months.

Interventions

OTHERMedcheck message

Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician

Sponsors

Agency for Healthcare Research and Quality (AHRQ)
CollaboratorFED
Blue Cross Blue Shield
CollaboratorOTHER
Beth Israel Deaconess Medical Center
CollaboratorOTHER
Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients \>18 * Patients that receive a new prescription * Proficient in spoken and written english

Design outcomes

Primary

MeasureTime frame
To prevent adverse drug events with PatientSite.3 years

Secondary

MeasureTime frame
Improve patient satisfaction3 years
better utilization of services3 years
improve patient-clinician communication3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026